Pharmaceutical Executive Weekly:CSL Cuts Jobs, Pfizer’s Sickle Cell Setback, and Eli Lilly Expands Zepbound Access

In this week’s Pharmaceutical Executive Weekly, we cover CSL’s decision to cut 15% of its U.S. workforce and close 22 plasma centers, Pfizer’s Phase 3 trial failure in sickle cell disease, and Eli Lilly’s new LillyDirect program expanding full-dose Zepbound access for obesity patients.